Amplia Therapeutics Liabilities 2024

Amplia Therapeutics Aktienanalyse

What does Amplia Therapeutics do?

Amplia Therapeutics Ltd was originally founded in 2012 and is based in Sydney, Australia. The company focuses on the development of novel therapies for cancer and other serious diseases. Amplia's main focus is on the development of peptide-based therapeutics, which are polypeptides derived from naturally occurring proteins. The company also places special emphasis on non-coding RNA (ncRNA) research and is working on the discovery, development, and commercialization of drugs that specifically target ncRNA. Amplia already holds various patents and approvals in this field. Amplia's core business is the research and development of drugs for cancer. The company collaborates with academic research groups and institutions worldwide and works closely with manufacturers of synthetic peptides to ensure high quality and efficacy in drug production. Amplia has developed various drug platforms to support its research activities. One of these platforms is the peptide library, which contains a large collection of synthetic peptides that can be used against different types of cancer. Another platform is ncRNA-based therapeutics, which exert their effects by inhibiting ncRNA molecules. Currently, Amplia Therapeutics has several drugs in various stages of clinical development. One example is AMP945, a peptide designed as a potential medication for triple-negative breast cancer. The drug targets a protein receptor found on the surface of cancer cells and has shown promising results in inhibiting tumor growth in animal models. Another example is ATX101, an ncRNA inhibitor also being developed as a potential medication for cancer. The inhibitor targets a specific form of ncRNA molecule that is overproduced in various types of cancer. In animal models, the drug has shown promising results in preventing tumor progression. Overall, Amplia Therapeutics Ltd aims to develop drugs that can significantly improve the lives of patients. The company strives to set new standards in cancer therapy and continuously works to improve its technology platforms and expand its product pipeline. Amplia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Amplia Therapeutics's Liabilities

Amplia Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Amplia Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Amplia Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Amplia Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Amplia Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Amplia Therapeutics stock

What is the level of liabilities of Amplia Therapeutics this year?

Amplia Therapeutics has a debt balance of 3.43 M AUD this year.

What were the liabilities of Amplia Therapeutics compared to the previous year?

The liabilities of Amplia Therapeutics have increased by 30% increased compared to the previous year.

What are the consequences of high debt for investors of Amplia Therapeutics?

High liabilities can pose a risk for investors of Amplia Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Amplia Therapeutics?

Low liabilities mean that Amplia Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Amplia Therapeutics affect the company?

An increase in liabilities of Amplia Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Amplia Therapeutics affect the company?

A decrease in the liabilities of Amplia Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Amplia Therapeutics?

Some factors that can influence the liabilities of Amplia Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Amplia Therapeutics so important for investors?

The liabilities of Amplia Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Amplia Therapeutics take to modify the liabilities?

To change its liabilities, Amplia Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Amplia Therapeutics pay?

Over the past 12 months, Amplia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amplia Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Amplia Therapeutics?

The current dividend yield of Amplia Therapeutics is .

When does Amplia Therapeutics pay dividends?

Amplia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amplia Therapeutics?

Amplia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Amplia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amplia Therapeutics located?

Amplia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amplia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amplia Therapeutics from 10/2/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Amplia Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Amplia Therapeutics in the year 2023?

In the year 2023, Amplia Therapeutics distributed 0 AUD as dividends.

In which currency does Amplia Therapeutics pay out the dividend?

The dividends of Amplia Therapeutics are distributed in AUD.